Watching Vaxart, Inc.? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planVaxart, Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Vaxart announced a reorganization of its Board committees on July 27, 2026, with Kevin P. Finney appointed as chair of the Nominating and Governance Committee and James B. Breitmeyer, M.D., Ph.D. as chair of the Compensation Committee, effective August 1, 2026. This governance restructuring may influence strategic oversight and decision-making.
Key Takeaways
Kevin P. Finney assumes leadership of the Nominating and Governance Committee, responsible for board composition and corporate governance matters
James B. Breitmeyer, M.D., Ph.D. takes over the Compensation Committee, overseeing executive compensation and incentive structures
2 more takeaways
Filing Overview
What This Means
Vaxart, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.